Key facts
- This page summarizes Jean Jacques Bienaime's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 May 2024, 15:57.
Jean Jacques Bienaime - 09 May 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- Director
- Issuer ticker
- BMRN
- Reported as of
- 09 May 2024
- Net transaction value
- -$731,200
- SEC form
- 4
- Accepted by SEC
- 13 May 2024, 15:57:27 UTC
- Prior SEC filing
- 15 Apr 2024
- Next SEC filing
- 21 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jean Jacques Bienaime filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 13 May 2024.
Change
- Previous filing in this sequence was filed on 15 Apr 2024.
- Current net transaction value: -$731,200.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Options Exercise
- Transaction value
- $1,262,000
- Shares
- +20,000
- Change %
- +4.2%
- Price
- $63.10
- Shares after
- 494,994
- Date
- 09 May 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Sale
- Transaction value
- $1,632,400
- Shares
- -20,000
- Change %
- -4%
- Price
- $81.62
- Shares after
- 474,994
- Date
- 09 May 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Options Exercise
- Transaction value
- $1,262,000
- Shares
- +20,000
- Change %
- +4.2%
- Price
- $63.10
- Shares after
- 494,994
- Date
- 10 May 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Sale
- Transaction value
- $1,622,800
- Shares
- -20,000
- Change %
- -4%
- Price
- $81.14
- Shares after
- 474,994
- Date
- 10 May 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 247,333
- Date
- 09 May 2024
- Ownership
- Shares held by Jean-Jacques Bienaime Family Trust
BMRN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100
- Date
- 09 May 2024
- Ownership
- Shares held as UTMA custodian for child 1
BMRN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100
- Date
- 09 May 2024
- Ownership
- Shares held as UTMA custodian for child 2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -22%
- Price
- $0.000000
- Shares after
- 71,000
- Date
- 09 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $63.10
- Footnotes
- F2
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Options Exercise
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -28%
- Price
- $0.000000
- Shares after
- 51,000
- Date
- 10 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $63.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
Footnote F2
Reflects the number of options outstanding after the transactions from this specific stock option grant.